Gene test to watch for liver cancer return after treatment
Part of Cancer, Digestive system clinical trials.
This study is testing a new gene test (GNB4 and Riplet) to monitor liver cancer patients for possible return of cancer after treatment. It is designed for people who have liver cancer and are having surgery, transplant, ablation, or TACE treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You need to have liver cancer (or be strongly suspected of it) and be planning one of these treatments: surgery, transplant, ablation, or TACE.
- If you've had previous liver cancer treatment but still have the tumor, you can join if you're planning another of those treatments.
- If you've already had one of these treatments for liver cancer, you need to have had a positive result on this study's test before that treatment.
- Samples like blood or tissue must be collected and stored correctly before your treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new blood test that looks for DNA from cancer cells' mitochondria to see if it can catch liver cancer coming back earlier. The goal is to help doctors find recurrence faster and improve follow-up care.
This study looks at special blood markers in people with liver cancer (hepatocellular carcinoma) who are about to have a procedure called TACE. The goal is to see if these markers can help predict how well the treatment works. You may be able to join if you are getting TACE as part of your standard care.
This trial looks at a specific gene (LINC01134) to see if it helps liver cancer spread in people with hepatitis C. The goal is to better understand why some cancers spread, which could lead to new treatments.
This trial uses a blood test to check for signs of liver cancer coming back after treatment. It may help find recurrence earlier than standard scans.
This study checks whether a blood test (circulating tumor DNA) can help predict if hepatocellular carcinoma (HCC) will return after curative treatment like surgery or ablation. If it works, it may help doctors plan closer follow-up or earlier treatment if recurrence risk is higher.
This study uses a simple blood test to monitor tiny pieces of tumor DNA (ctDNA) in people with colorectal cancer that spread to the liver or with liver cancer (HCC), before and after liver surgery or transplant. It aims to help doctors detect cancer return earlier and guide treatment.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.